S

在45只切断双侧缓冲神经的Sprague-Dawley 大鼠,应用细胞外记录方法, 观察了颈动脉内注射腺苷对76 个最后区 (AP) 神经元自发放电活动的影响。所得结果如下(1) 在记录到的42个自发放电单位中, 颈动脉内注射腺苷(25 μg/kg) 引起其中29个单位的放电频率由6.26±0.75 下降至4.74±0.76 spikes/s (P<0.01), 6 个单位放电频率由4.13±0.77增加至4.72±0.83 spikes/s (P<0.05),另外7个单位放电频率无明显变化, 而血压和心率在实验中无变化; (2)在应用非选择性腺苷受体拮抗剂8-苯茶碱(8-phenyltheophylline, 15 μg/kg) 的10个单位, 腺苷对放电的抑制效应可被完全阻断; (3) 应用选择性腺苷A     

肾上腺髓质素对大鼠延髓头端腹外侧区压力反射敏感神经元的作用

采用多管微电泳结合细胞外记录的方法研究了肾上腺髓质素(adrenomedullin,ADM)对大鼠延髓头端腹外侧区(rostral ventrolateral medulla,rVLM)压力反射敏感性神经元电活动的作用及其可能机制.结果显示在29个rVLM压力反射敏感神经元中,20个神经元在30、60和90 nA的电流微电泳大鼠ADM(rADM)过程中,放电频率由(10.8±2.7)spikes/s分别增加到(14.6±3.6)、(19.8±4.7)和(31.9±6.4)spikes/s(P＜0.05,n=20).微电泳rADM特异性受体阻断剂人ADM(human ADM,hADM)(22-52)可明显减小神经元放电频率的增加幅度,比正常放电频率仅增加15.4%[(11.4±2.5)sipkes/s,P＜0.05,n=10],而降钙素基因相关肽1(CGRP1)受体阻断剂hCGRP(8-37)对rADM兴奋性神经元电活动影响较小.在另外23个神经元中,10个神经元的放电频率在10、20和40 nA电流微电泳神经型NOS(nNOS)抑制剂7-NiNa过程中放电减少,由正常的(10.1±3.5)spikes/s分别减少为(7.5±2.5)、(5.3±2.1)和(3.1±1.4)spikes/s(P＜0.05,n=10).在微电泳7-NiNa过程中同时微电泳rADM,则rADM增加神经元放电频率的效应减弱,增加幅度为基础水平的17%[(6.2±1.9)spikes/s].8个神经元在10、20和40 nA电流微电泳诱导型NOS抑制剂(iNOS)aminoguanidine(AG)过程中放电频率由(11.5±5.1)spikes/s增加到(17.8±5.6)、(22.5±6.3)和(29.1±6.4)spikes/s(P＜0.05,n=8),rADM与AG同时微电泳时,AG对rADM本身增加神经元放电的效应无明显影响.上述结果提示,rADM在rVLM可通过其特异性受体或来源于nNOS的NO作用于压力反射敏感神经元,使其活动增强而发挥调节心血管活动的作用.     

腺苷对家兔颈动脉体化学感受器活动的影响

在39只乌拉坦麻醉家兔,记录了腺苷作用于颈动脉体时窦神经化学感受性传入单位的放电活动。全部实验中共记录了73个有自发放电的化学感受性单位。所得结果如下:(1)颈动脉内注射腺苷(10ug/kg)时,在55个单位中有51个的放电频率由0.76±0.10增加到1.53±0.23 imp/s(P<0.001),部分实验中有新的单位被激活。(2)在隔离的颈动脉窦灌流液中加入腺苷(0.5,1.0、5.0、10、50和100μg/kg)时,9个单位的放电频率由0.51±0.06分别增加到0.58±0.07、0.78±0.13、0.96±0.15、1.11±0.017、1.34±0.21和1.38±0.18imp/s,有明显的剂量依赖性(P<0.001).(3)9个自发放电频率为1.30±0.40 imp/s 的单位,在颈动脉内注射多巴胺(50μg/kg)后,其放电频率减慢至0.56±0.19imp/s(P<0.001)。在多巴胺作用的基础上再注射腺苷。可使放电频率增加到1.07±0.28imp/s,但与注射多巴胺前的腺苷效应相比,此增值明显减小(P<0.001)。根据以上结果,我们推测腺苷对颈动脉体化学感受器的兴奋作用,可能与其作用于感受器复合体的突触前膜,从而使颈动脉体内抑制性递质多巴胺释放减少,以及腺苷直接兴奋化学感受性神经末梢有关。     

颈动脉注射17β -雌二醇对去缓冲神经大鼠延髓腹外侧头端区神经元放电活动的影响

本研究旨在观察17β-雌二醇(E2)对雄性大鼠延髓腹外侧头端区(RVLM)神经元自发放电活动的影响.在切断双侧缓冲神经的麻醉雄性Sprague-Dawley大鼠上,同步记录血压、心率和RVLM神经元的自发放电活动.颈动脉内注射E2 (10 ng/kg),30个RVLM神经元自发放电单位中有25个单位的放电频率由14.46±0.47降至9.73±0.33 spikes/s (P<0.05),与此同时血压和心率无明显改变.E2的抑制效应在1 min内起效,持续时间长于5 min.雌激素受体拮抗剂tamoxifen (5 mg/kg)不能阻断E2 的抑制效应.预先给予一氧化氮(NO)合酶阻断剂L-NAME (2.7 μg/kg)能明显阻断E2的抑制效应.应用NO供体SIN-1 (0.5 μg/kg)可增强E2的抑制效应.以上结果提示,E2可通过非基因组效应激活RVLM神经元的NOS而引发NO释放,进而抑制其自发放电活动.     

17β-雌二醇对大鼠脑片穹隆下器神经元放电活动的调变作用

用细胞外记录技术 ,在大鼠脑片穹隆下器 (subfornicalorgan ,SFO)上观察了 17β 雌二醇 (17β estradiol,E2 )对SFO神经元放电的影响 ,并进而分析其作用机制。实验结果如下 :(1) 15个SFO神经元在给予小剂量E2(0 1nmol/L)时 ,放电频率由 3 2 1± 0 37增至 6 79± 0 71Hz(P <0 0 0 1) ;而在给予大剂量E2 (10 0nmol/L)时 ,则放电频率由 3 44± 0 40Hz降至 1 44± 0 36Hz (P <0 0 1) ;(2 )在 7个SFO神经元应用谷氨酸NMDA受体阻断剂MK 80 1(5 0pmol/L) ,可阻断小剂量E2 (0 1nmol/L)对SFO神经元的兴奋效应 ;(3)在 7个SFO神经元应用NO生理性前体L 精氨酸 (L arginine ,1mmol/L)时 ,SFO神经元放电减少 ,且可阻断小剂量E2 (0 1nmol/L)对神经元的兴奋效应 ;(4 )在 6个SFO神经元应用NOS抑制剂L NG 硝基精氨酸甲酯 (L NAME ,10mmol)引起SFO神经元放电增加 ,并阻断大剂量E2 (10 0nmol/L)对SFO神经元的抑制效应。结果提示 :E2 对SFO神经元有双重作用。小剂量E2 使SFO神经元放电增加 ,这一效应可能与谷氨酸受体激活有关 ;而大剂量E2 则导致神经元放电减少 ,此效应可归因于NOS激活而引发NO生成。     

肾缺血增强大鼠延髓腹外侧头端区神经元电话动和Fos蛋白表达

在67只切断两侧缓冲神经的麻醉Sprague-Dawley大鼠,应用细胞外记录的电生理方法和免疫组织化学技术,分别观察肾缺血对延髓腹外侧头端区巨细胞旁外侧核神经元自发放电活动和Fos蛋白表达的影响.所得结果如下(1)左肾动脉阻断后,28个单位的放电频率由11.40±1.08增至21.1±1.74spikes/s(P<0.001),血压和心率无明显变化(P>0.05);(2)在17个放电单位中,应用腺苷受体拮抗剂8-苯茶碱(8-phenyltheophylline,10mg/kg)可明显抑制肾缺血的兴奋效应(P<0.05);(3)肾缺血后,延髓腹外侧头端区的Fos蛋白样免疫反应神经元显著增加(P<0.01);(4)预先应用8-苯茶碱可明显减弱肾缺血所激活的Fos蛋白表达反应(P<0.05).以上结果提示肾缺血增强延髓腹外侧头端区神经元的放电活动和Fos蛋白表达,而此作用可能与肾脏缺血所产生的腺苷激活肾内感受器有关.     

心室内和心外膜应用腺苷对延髓PGL神经元电活动的影响

在35只切断两侧缓冲神经和迷走神经的麻醉大鼠,观察心室内注射腺苷和心外膜涂布腺苷对延髓腹外侧头端区PGL神经元自发电活动的影响。结果如下：（1）35只大鼠共记录到121个自发放电单位,平均放电频率为22．5±1．9spikes／s。（2）心室内冲击注射腺苷（0．5μmol/kg,0．1ml）时,BP先升（△1．7±0．2kPa,P＜0.001）后降（△4.6土0.5kPa,P＜0．001）,HR减慢（△126．5±12.3bpm,P＜0.001）;35个PGL神经元自发放电单位中,30个单位的放电频率由21．9士2．6增至29．2土3．4spikes／s（P＜0．001）,3个单位不变,2个单位减少。（3）心外膜涂布腺苷（20mmol/L）,动脉血压和心率的变化不明显,22个PGL神经元自发放电频率由18．8土1．9增至26．9土2．8spikes／s（P＜0．001）,3个单位的放电频率无变化。（4）静脉注射选择性腺苷A1受体拮抗8－cyclopentyl-1,3－dipropylxanthine（DPCPX,500μg／kg）可完全阻断腺苷对PGL神经元的兴奋效应。（5）在左右房室沟涂布85％酚或切除双侧星状神经节后,腺苷激活PGL神经元的效应即行消失。结果提示,腺苷可通过人受体激活心交感神经传入纤维,进而兴奋PGL神经元。     

大鼠下丘脑外侧区内微量注射胃动素对胃窦运动和迷走背核复合体神经元电活动的影响

采用清醒大鼠胃运动记录和玻璃微电极记录神经元活动的实验方法 ,研究下丘脑外侧区 (lateralhy pothalamicarea,LHA)微量注射胃动素 (motilin) ,对清醒大鼠胃窦运动和对麻醉大鼠迷走背核复合体 (dorsalvagalcomplex ,DVC)中胃扩张敏感神经元电活动的调节作用。LHA内微量注射胃动素 (0 37nmol/ 0 5 μl)可使胃窦运动增强 76 2 9± 4 0 9% (P <0 0 1)。DVC中 6 0个胃扩张 (gastricdistention ,GD)敏感神经元中 ,39(6 5 % )个GD刺激引起电活动增强 ,2 1(35 % )个电活动减弱 ,分别称之为GD兴奋型神经元和GD抑制型神经元。双侧LHA微量注射胃动素 0 37nmol/ 0 5 μl,14个GD抑制型神经元中有 12个单位放电频率增加 4 4 35± 7 89% (P <0 0 1) ;2 4个GD兴奋型神经元中有 15个单位放电频率减少 7 17± 7 89% (P <0 0 5 )。结果提示 ,中枢胃动素可能通过LHA-DVC-迷走神经实现对胃窦运动的调控     

颈动脉内注射腺苷对去缓冲神经大鼠最后区神经元放电的影响

在45只切断双侧缓冲神经的SpragueDawley大鼠,应用细胞外记录方法,观察了颈动脉内注射腺苷对76个最后区(AP)神经元自发放电活动的影响。所得结果如下:(1)在记录到的42个自发放电单位中,颈动脉内注射腺苷(25μg/kg)引起其中29个单位的放电频率由626±075下降至474±076spikes/s(P<001),6个单位放电频率由413±077增加至472±083spikes/s(P<005),另外7个单位放电频率无明显变化,而血压和心率在实验中无变化;(2)在应用非选择性腺苷受体拮抗剂8苯茶碱(8phenyltheophylline,15μg/kg)的10个单位,腺苷对放电的抑制效应可被完全阻断;(3)应用选择性腺苷A1受体拮抗剂8环戊1,3二丙基黄嘌呤(8cyclopentyl1,3dipropylxanthine,50μg/kg)亦可有效地阻断腺苷对12个单位的抑制效应;(4)应用ATP敏感性钾通道阻断剂格列苯脲(500μg/kg)的12个单位,腺苷的上述效应也被消除。以上结果提示,腺苷对AP区神经元自发放电有抑制作用,而此作用与A1受体介导的ATP敏感性钾通道开放有关。     

辣椒素对大鼠延髓腹外侧头端区神经元电活动的影响

在35只切断两侧缓冲神经的麻醉大鼠,应用细胞外记录的电生理学方法,观察颈总动脉注射辣椒素(capsaicin)对延髓腹外侧头端区(RVLM)巨细胞旁外侧核(PGL)自发电活动的影响。所得结果如下:(1)颈动脉注射辣椒素(10μmol,01ml),MAP由1074±013升至1256±021kPa(P<0001);HR由374±4增至395±5bpm(P<0001);30个PGL神经元自发放电单位的放电频率由126±07增至209±11spikes/s(P<0001)。(2)在10个放电单位,应用辣椒素受体阻断剂钌红(rutheniumred;200mmol,01ml)后,明显抑制辣椒素的上述效应。以上结果提示,辣椒素可能通过激活RVLM神经元上的辣椒素受体,进而兴奋PGL神经元     

内皮素通过最后区易化大鼠延髓腹外侧头端区神经元活动

在３５只切断双侧缓冲神经、用氨基甲酸乙酯－α氯醛糖混合麻醉的Ｓｐｒａｇｕｅ－Ｄａｗｌｅｙ大鼠,应用细胞外记录的电生理学方法,由ＲＭ－６０００型多道生理记录仪和ＷＳ－６８２Ｇ热阵记录器（频响范围０～２．８ｋＨｚ）同步记录血压、心率和单位神经元放电,观察颈动脉注射内皮素对８７个延髓腹是头端区（ＲＶＬＭ）自发放电神经元活动的影响,所得结果如下;（１）颈动脉注射ＥＴ－１（０．３ｎｍｏｌ／ｋｇ）时３６个单位     

颈动脉内注射腺苷对去缓冲神经大鼠最后区神圣凶放电影响

To observe the effect of intracarotid administration of adenosine on the electrical activity of area postrema (AP) neurons, 76 spontaneous active units were recorded from 45 sino-aortic denervated Sprague-Dawley rats using extracellular recording technique. The results obtained are as follows. (1) Following intracarotid administration of adenosine (Ado, 25 micrograms/kg), the discharge rate of 29 out of 42 units decreased markedly from 6.26 +/- 0.75 to 4.74 +/- 0.76 spikes/s (P < 0.01), whereas that of 6 units increased from 4.13 +/- 0.77 to 4.72 +/- 0.83 spikes/s (P < 0.05), and the other 7 showed no response. Blood pressure (BP) and heart rate (HR) were unaltered throughout the experiment. (2) 8-phenyltheophylline (8-PT, 15 micrograms/kg), a nonselective adenosine receptor antagonist, completely blocked the inhibitory effect of Ado in 10 units. (3) Selective A1 adenosine receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 50 micrograms/kg), blocked the effect of Ado in 12 units to a remarkable extent. (4) Glibenclamide (500 micrograms/kg), a blocker of ATP-sensitive potassium channel, abolished the effect of Ado in 12 units. The above results indicate that Ado can inhibit spontaneous electrical activity of AP neurons, which is mediated by adenosine A1-receptor with the involvement of ATP-sensitive potassium channels.     

延髓腹外侧头端区注射肾上腺髓质素对大鼠血压、心率和肾交感神经活动的影响

本研究在 3 4只麻醉Sprague Dawley大鼠观察了延髓腹外侧头端区内微量注射肾上腺髓质素 ( 10μmol/L ,2 0 0nl)对平均动脉压 (MAP)、心率 (HR)和肾交感神经放电 (RSNA)的影响。实验结果如下 :( 1)延髓腹外侧头端区内微量注射肾上腺髓质素可引起MAP、HR、和RSNA明显增加 ,分别由 99 0 9± 3 3 2mmHg ,3 70 78± 7 84bpm和 10 0± 0 %增至 113 5 7± 3 64mmHg (P <0 0 0 1) ,3 83 2 8± 7 3 8bpm (P <0 0 0 1)和 12 3 72±2 74% (P <0 0 0 1) ;( 2 )降钙素基因相关肽受体阻断剂CGRP8 3 7( 10 0 μmol/L ,2 0 0nl)不能阻断肾上腺髓质素的上述效应 ;( 3 )静脉注射NO前体L 精氨酸 ( 10 0mg/kg ,0 2ml)可消除肾上腺髓质素的上述效应。以上结果提示 ,肾上腺髓质素作用于延髓腹外侧头端区可产生显著的心血管作用 ,此作用不是由降钙素基因相关肽受体介导 ,但可被NO所阻断     

颈动脉注射腺苷对去缓冲神经大鼠延髓腹外侧头端区神经元放电的影响

在28只切断双侧缓冲神经的Sprague－Dawley大鼠,应用细胞外记录方法,观察了72个自发放电单位中颈动脉注射腺苷对延髓腹外侧头端（RVLM）区神经元自发放电活动的影响。所得结果如下：（1）颈动脉注射腺苷（25μg/kg）,31个单位的放电频率由23．5±3．0下降至（16．5±2．6）spikes／s（P＜0．001）,血压和心率无明显变化（P＞0．05）;（2）在24个单位中,应用非选择性腺苷受体拮抗剂8-苯茶碱（8-phenyltheophylline,15μg/kg）和选择性腺苷A1受体持抗剂8-环戊-1,3-二丙基黄嘌呤（8－cyclopentyl-1,3－dipropylxanthine,50μg/kg）均可完全阻断腺苷的抑制效应;（3）在应用ATP敏感性钾通道阻断剂格列苯脲（500μg/kg）的12个单位中,腺苷的上述效应亦被消除。以上结果提示,腺苷对RVLM区神经元自发放电有抑制作用,而此作用与A1受体介导的ATP敏感性钾通道开放有关。     

侧脑室注射肾上腺髓质素增加大鼠心血管相关核团中c-fos的表达并激活脑内一氧化氮神经元

本研究利用Fos蛋白和一氧化氮合酶(nNOS)双重免疫组化方法,观察侧腑脑室注射肾上腺髓质素(adrenomedullin,ADM)对大鼠心血管相关核中c-fos表达及一氧化氮神经元的影响,以探讨ADM在中枢的作用部位并研究其在中枢的作用是否有NO神经元参与。侧脑室注射ADM(1nmol／kg,3nmol／kg)诱发脑干的孤束核、最后区、蓝斑核、臂旁核和外侧巨细胞旁核,下丘脑的室旁核、视上核才腹内侧核以及前脑的中央杏仁核和外侧缰核等多个部位的心血管中枢出现大量Fos样免疫反应神经元。侧脑室注射ADM(3nmol／kg),引起脑干的孤束核、外侧巨细胞旁核,下丘脑的室旁核、视上核内的Fos-nNOS双标神经元增加;ADM(1nmol／kg)亦可引起室旁核、视上核内的Fos-nNOS双标神经元增加,而对孤束核、外侧巨细胞旁核内的Fos-nNOS双标神经元无影响。降钙素基因相关肽(calcitonin gene—related peptide,CGRP)受体拈抗剂CGRP8-37(30nmol／kg)可明显减弱此效应。以上结果表明,ADM可兴奋脑内多个心血管相关核闭的神经元并激活室旁核、视上核、孤束核及外侧巨细胞核内一氧化氮神经元,此效应可能部分山CGRP受体介导。     

Intracerebroventricular injection of <Emphasis Type="SmallCaps">l</Emphasis>-arginine induces sedative and hypnotic effects under an acute stress in neonatal chicks

L-arginine participates in many important and diverse biochemical reactions associated with the normal physiology of the organism. In the present study, we investigated the effect of central administration of L-arginine on the stress response and its mechanism in neonatal chicks. Intracerebroventricular (i.c.v.) injection of L-arginine clearly attenuated the stress response in a dose-dependent manner, and induced sleep-like behavior during 10 min. To clarify the mechanism by which L-arginine induces sedative and hypnotic effects in chicks, we investigated the effects of nitric oxide (NO) synthase (NOS) inhibitors on L-arginine-induced sedative and hypnotic effects, and as well as the effects of a NO donor. L-Arginine-induced (1.9 micromol) sedative and hypnotic effects were attenuated by i.c.v. co-injection with a non-selective NOS inhibitor N(G)-nitro-L-arginine methyl ester HCl (400 nmol). In addition, the effects of L-arginine were slightly attenuated by the inactive isomer of the NOS inhibitor N(G)-nitro-D-arginine methyl ester HCl (400 nmol). The i.c.v. injection of 3-morpholinosylnomine hydrochloride, a spontaneous NO donor, had little effect on postures. The i.c.v. injection of L-arginine had no effect on NOx concentration at various brain sites. These results suggested that the contribution of NO generation via NOS may be low in the sedative and hypnotic actions of L-arginine. Therefore, L-arginine and/or its metabolites, excluding NO, may be necessary for these actions.     

Acute and chronic responses associated with adrenomedullin administration in experimental colitis

Adrenomedullin (AM) is a 52 amino acid peptide and member of the calcitonin gene-related peptide (CGRP) super family. Given that AM has emerged as a potential immuno-regulatory and anti-inflammatory agent in various experimental models, this study has deepened into its possible therapeutic effect in intestinal inflammation analyzing the responses in both acute and chronic (14 and 21 days) phases of TNBS-induced colitis in rats. In the acute model, AM treatment reduced the incidence of diarrhea and the severity of colonic damage, and improved the survival rate at the three doses assayed (50, 100, and 200ng/kg animal). AM administration was able to reduce the early production of TNF-alpha and collaborated to maintaining basal levels of IFN-gamma and IL-10. In the chronic studies the peptide attenuated the extent of the damage with lesser incidence of weight loss and diarrhea (50 and 100ng/kg animal). Cellular neutrophil infiltration, with the subsequent increase in myeloperoxidase (MPO) levels caused by TNBS, was reduced after chronic AM administration. The peptide played a role in the evolution of Th1/Th2 cytokines balance and chronic disease recuperation: levels of proinflammatory TNF-alpha and IFN-gamma decreased and anti-inflammatory IL-10 increased significantly. Cyclooxygenase-2 (COX-2) and nitric oxide synthase (iNOS) protein expression were not modified by AM administration, although a reduction of nitric oxide (NO) production could be detected in the chronic model. These results support a role of AM as an anti-inflammatory factor with beneficial effects in intestinal inflammatory colitis.     

Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats

This study examined if the nitric oxide (NO)/L-arginine pathway participates in and if the sympathetic nervous system attenuates the depressor action of human urotensin II. I.V. bolus injections of human urotensin II (0.1-30 nmol/kg) caused dose-dependent decreases in mean arterial pressure (MAP, EC(50) = 2.09 +/- 0.8 nmol/kg; Emax = -18 +/- 3 mmHg ) and increases in heart rate. The depressor response to human urotensin II (3 nmol/kg) was attenuated by approximately 50% in rats with MAP elevated through pretreatment with N(G)-nitro-L-arginine methyl ester (inhibitor of NO synthase), relative to that in rats with MAP elevated to a similar level through a continuous infusion of noradrenaline. Autonomic blockade with i.v. injections of mecamylamine (ganglion blocker) and propranolol (beta-adrenoceptor antagonist) markedly augmented the depressor response to human urotensin II, but almost completely attenuated the tachycardia. The results suggest that the depressor response to human urotensin II is partially mediated via the NO/L-arginine pathway, and is suppressed by activity of the sympathetic nervous system. Furthermore, tachycardic response to human urotensin II is primarily mediated indirectly via baroreflex mechanisms.     

Centrally administered adrenomedullin 2 activates hypothalamic oxytocin-secreting neurons, causing elevated plasma oxytocin level in rats

We examined the effects of intracerebroventricular (i.c.v.) administration of adrenomedullin 2 (AM2) on plasma oxytocin (OXT) and arginine vasopressin (AVP) levels in conscious rats. Plasma OXT levels were markedly increased 5 min after i.c.v. administration of AM2 (1 nmol/rat) compared with vehicle and remained elevated in samples taken at 10, 15, 30, and 60 min. By contrast, plasma AVP levels were not significantly elevated in samples taken between 5 and 180 min after i.c.v. administration of AM2 except at the 30-min time point. Fos-like immunoreactivity (Fos-LI) was observed in various brain areas, including the paraventricular (PVN) and the supraoptic nuclei (SON) after i.c.v. administration of AM2 (2 nmol/rat) in conscious rats (measured at 90 min post-AM2 infusion). Dual immunostaining for OXT/Fos and AVP/Fos showed that OXT-LI neurons predominantly exhibited nuclear Fos-LI compared with AVP-LI neurons in the PVN and the SON. In situ hybridization histochemistry showed that i.c.v. administration of AM2 (0.2, 1, and 2 nmol/rat) caused marked induction of the expression of the c-fos gene in the PVN and the SON. This induction was significantly reduced by pretreatment with both the calcitonin gene-related peptide (CGRP) antagonist CGRP-(8-37) (3 nmol/rat) and the AM receptor antagonist AM-(22-52) (27 nmol/rat). These results suggest that centrally administered AM2 mainly activates OXT-secreting neurons in the PVN and the SON, at least in part through the CGRP and/or AM receptors with marked elevation of plasma OXT levels in conscious rats.